Modality
Bispecific Ab
MOA
MALT1i
Target
IL-23
Pathway
Sphingolipid
PsoriasisRA
Development Pipeline
Preclinical
~Jul 2010
→ ~Oct 2011
Phase 1
~Jan 2012
→ ~Apr 2013
Phase 2
~Jul 2013
→ ~Oct 2014
Phase 3
~Jan 2015
→ ~Apr 2016
NDA/BLA
~Jul 2016
→ ~Oct 2017
Approved
Jan 2018
→ Sep 2030
ApprovedCurrent
NCT07931894
2,078 pts·Psoriasis
2018-01→2028-04·Recruiting
NCT03078208
489 pts·Psoriasis
2021-11→2030-09·Terminated
NCT04491307
1,722 pts·Psoriasis
2022-01→2027-08·Recruiting
4,289 total pts1 indication
CompletedCurrentUpcoming
Catalysts (3)
2027-08-181.4y awayPh3 Readout· Psoriasis
2028-04-172.0y awayPh3 Readout· Psoriasis
2030-09-044.4y awayPh3 Readout· Psoriasis
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Approved
Recruit…
Approved
Termina…
Approved
Recruit…
Catalysts
Ph3 Readout
2027-08-18 · 1.4y away
Psoriasis
Ph3 Readout
2028-04-17 · 2.0y away
Psoriasis
Ph3 Readout
2030-09-04 · 4.4y away
Psoriasis
RecruitingTerminated|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07931894 | Approved | Psoriasis | Recruiting | 2078 | OS |
| NCT03078208 | Approved | Psoriasis | Terminated | 489 | DOR |
| NCT04491307 | Approved | Psoriasis | Recruiting | 1722 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 |